Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun
as Chief Executive Officer (CEO). He will take up the position on 6 April 2021
and will be based in the company's office in Zug, Switzerland.

Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with
extensive commercialisation experience with innovative oncology products and
deep knowledge of pharmaceutical markets worldwide from a career spanning nearly
30 years at Hoffmann-La-Roche ("Roche").

During his career at Roche, Mr Braun led the Lifecycle Management teams for the
successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva®
(erlotinib).

Mr Braun has also held various operational leadership positions including being
country general manager and multiple commercial roles in Europe, US and Latin
America. He has developed expertise across multiple strategic and operational
roles including development, manufacturing, business development and market
access for innovative therapeutic products in several geographies and other
therapeutic areas, including rare diseases and infectious diseases.

In addition to his experience at Roche, Mr Braun has also held roles at an
artificial intelligence (AI)-driven life sciences start-up and as strategy
consultant to emerging healthcare companies.

Jan H. Egberts, Chairman of Nordic Nanovector's Board of Directors, said: "I am
delighted that Peter has agreed to join us at this important time for Nordic
Nanovector. Our aim was to leverage on our important recent progress by
recruiting a strong commercial CEO who can refine and drive the company's plans
towards the regulatory filing and commercialisation of Betalutin®. We are
confident that, with Peter's track record in and enthusiasm for the development
and commercialisation of innovative targeted oncology products, we can build on
the top-line data from the PARADIGME trial expected later in the year by clearly
defining our plans for Betalutin®'s commercialisation. These are key steps on
our path to becoming a leader in targeted radiopharmaceuticals."

"I would like to take this opportunity to thank Lars Nieba for his leadership of
the company during the last 12 months as Interim CEO. His dedication and efforts
have contributed to the considerable progress Nordic Nanovector has made in this
time."